First immediate-release PPI hits pharmacy shelves
For well over a decade, proton pump inhibitors (PPIs) have been considered the first-line treatment for gastroesophageal reflux disease, or GERD. In 2003, U.S. sales of the five delayed-release PPI brands totaled $12.9 billion, with total U.S. prescriptions for PPIs growing 10%, from 86.3 million in 2002 to 95.2 million in 2003, according to IMS Health.
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Related Content
